drugset / Trial / NCT06068686
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to evaluate the effect of vildagliptin on copeptin in comparison to glimepiride, and whether copeptin could be used as a marker for the efficacy of vildagliptin in type 2 diabetes mellitus patients, and how copeptin correlates with other diabetic and cardiac markers.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2024-11-30
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glimepiride | Small molecule | 3 mg | Oral |
| Subject | Vildagliptin | Other / unclassified | 50 mg | — |